Recent investigations have focused on the overlap of glucagon-like peptide-1|glucose-dependent insulinotropic polypeptide|GCGR activator therapies and dopaminergic neurotransmission. While GIP stimulators are commonly employed for managing type 2 diabetes, their potential effects on reinforcement circuits, specifically mediated by DA pathways, are